RPG Life Sciences Ltd
NSE: RPGLIFE BSE: 532983Pharma
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
₹2,290
52W: ₹1731 — ₹2725
PE 33.8 · Book ₹366 · +526% vs bookMarket Cap₹3,788 Cr
Stock P/E33.8Price to Earnings
ROCE26.2%Return on Capital
ROE19.8%Return on Equity
Div. Yield0.88%Face Value ₹8
Strengths
- +Company is almost debt free.
- +Company has delivered good profit growth of 22.9% CAGR over last 5 years
- +Company has been maintaining a healthy dividend payout of 28.8%
Weaknesses
- −Debtor days have increased from 46.5 to 60.2 days.
- −Working capital days have increased from 59.0 days to 107 days
Shareholding Pattern
Promoters72.95%
FIIs0.87%
DIIs7.45%
Public18.72%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.82% | 72.82% | 72.95%▲0.1 | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| FIIs | 1.15% | 1.35%▲0.2 | 1.3%▼0.1 | 1.46%▲0.2 | 1.35%▼0.1 | 1.11%▼0.2 | 1%▼0.1 | 0.87%▼0.1 |
| DIIs | 2.61% | 5.45%▲2.8 | 6.06%▲0.6 | 6.14%▲0.1 | 6.49%▲0.4 | 6.7%▲0.2 | 7.04%▲0.3 | 7.45%▲0.4 |
| Public | 23.44% | 20.4%▼3.0 | 19.7%▼0.7 | 19.46%▼0.2 | 19.22%▼0.2 | 19.23%▲0.0 | 19.01%▼0.2 | 18.72%▼0.3 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 |
| Expenses | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 |
| Operating Profit | 38 | 21 | 39 | 46 | 49 | 25 | 35 | 39 | 40 | 33 |
| OPM % | 25% | 16% | 24% | 27% | 28% | 18% | 21% | 21% | 22% | 19% |
| Net Profit | 26 | 13 | 27 | 4 | 35 | 117 | 26 | 37 | 22 | 30 |
| EPS ₹ | 16 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.9 | 22.28 | 13.38 | 18.08 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹708Cr, up 8.4% YoY. OPM at 21%.
Debt Position
Borrowings at ₹20Cr. Debt-to-equity ratio: 0.03x. Healthy balance sheet.
Capex Cycle
CWIP at ₹20Cr (10% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 7.45% (+7.18pp change). FIIs: 0.87% (+0.54pp change). Promoters hold 72.95%.
Margin & Efficiency
ROCE improving from 2% (Mar 2015) to 26% (Mar 2026). Working capital days: 107.
Valuation
PE 33.8x with 26.2% ROCE. Price is 526% above book value of ₹366. Dividend yield: 0.88%.
Recent Announcements
- Compliances-Reg.24(A)-Annual Secretarial Compliance 2d - Annual Secretarial Compliance Report for year ended March 31, 2026; no current deviations noted.
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 8 May - Company informed about Transcript of Earnings Call.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 30 Apr - Audio recording of Q4 FY26 results earnings call available on website on April 30, 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 30 Apr
- Announcement under Regulation 30 (LODR)-Investor Presentation 30 Apr
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse